A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

BioZone Scientific Technology Independently Confirmed to Be Effective Against SARS-CoV-2, the Virus That Causes COVID-19

December 10, 2020

BioZone Scientific Technology residential, commercial, and healthcare products were independently tested for effectiveness against SARS-CoV-2 by a third-party lab.

In the test report titled, “SARS-CoV-2 Surrogate Inactivation by Ultraviolet Disinfection System from BioZone Scientific,” the systems repeatedly delivered greater than 5-log inactivation (>99.999%) of the SARS-CoV-2 virus in less than one second of exposure to BioZone Scientific ultraviolet disinfection systems.

The testing was conducted by BioZone Scientific Technology Laboratories, an ISO/IEC 17025 certified Florida, USA-based lab which is also accredited by the US Centers for Disease Control, US Environmental Protection Agency, US Department of Agriculture, and Florida Department of Health. The test was designed to model exposure time comparative to inactivating the SARS-CoV-2 virus in the moving airstream within HVAC systems.

A leading manufacturer in HVAC UV light solutions for the disinfection of air and surfaces, BioZone ​Scientific technology has been used by thousands of people around the world for safe disinfection of homes, restrooms, transport, and businesses.

This study joins others, including those published in the Journal of Clinical Virology, that demonstrate that BioZone ​Scientific’s advanced ultraviolet disinfection systems are effective at inactivating viruses and other infectious diseases.

Paul Morris, BioZone ​Scientific’s Senior Vice President for Global Business Development, stated, “This is more welcome evidence that BioZone ​Scientific’s long experience of delivering innovative and effective Biological Defense systems for our clients is based on several critical philosophies – innovation, responsiveness to our clients’ needs, and sound, certified, scientific data. These accredited test results are the latest in a long line of groundbreaking and independently verified test programs that have been undertaken by BioZone Scientific, including research on the effectiveness of our technology against viruses by the French Centre for National Virology Research and papers published in the Journal of Clinical Virology.

This long term and consistent approach gives BioZone ​Scientific’s partners the confidence that they are working with technology that is always ahead of the field in terms of reliability, quality, and effectiveness. We believe this approach is at the center of our success, and the success of our clients.”

Ari Ahola, CEO of BioZone Scientific, stated, “These third-party test results show that BioZone Scientific systems are essential in delivering virus-free environments and are critical components of return to work protocols. In less than a second, BioZone solutions are capable of disinfection rates almost below the levels of detection. We’re immensely proud of these findings, which are well in line with other scientific tests of BioZone ​Scientific technologies. Our mission is to limit the spread of COVID-19 and help people to return to work safely.”

BioZone Scientific Technology is the leader in ultraviolet disinfection systems and has been at the forefront of UV technology for decades. It has a proven track record of innovation in disinfection technologies, which are designed, manufactured, and installed in line with the highest safety standards.

Visit BioZone ​Scientific Technology COVID-19 validation testing.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrusâ„¢ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

By using this website you agree to accept Medical Device News Magazine Privacy Policy